Product Line and Significant Customer Information

6 Months Ended

Jun. 30, 2011

Product Line and Significant Customer Information [Abstract]

Product Line and Significant Customer Information

Note 11 — Product Line and Significant Customer Information

     The Company currently operates in one business segment, the development, manufacturing, marketing, sales and support of molecular diagnostic products primarily to diagnose human diseases, screen donated human blood and ensure transplant compatibility.

     Product sales by product line for the three and six month periods ended June 30, 2011 and 2010 were as follows (in thousands):

	Three Months Ended June 30,										Six Months Ended June 30,
	2011					2010					2011					2010
	$		%			$		%			$		%			$		%
Clinical diagnostics	$	87,474		66	%	$	73,907		56	%	$	175,764		65	%	$	150,800		57	%
Blood screening		43,182		32	%		55,659		42	%		89,887		33	%		105,227		40	%
Research products and services		2,265		2	%		3,168		2	%		5,382		2	%		7,276		3	%
Total product sales	$	132,921		100	%	$	132,734		100	%	$	271,033		100	%	$	263,303		100	%

     During the six month periods ended June 30, 2011 and 2010, 34% and 42%, respectively, of the Company’s total revenues were from Novartis. No other customer accounted for more than 10% of the Company’s revenues during the three and six month periods ended June 30, 2011 and 2010.